Clinical Trial

A First-in-human Phase I Study to Evaluate EMB-15 in Patients With Locally Advanced or Metastatic Solid Tumors.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to evaluate safety and tolerability profile of EMB-15, identify the recommended Phase 2 dose(s) (RP2Ds) for EMB-15. Pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and the anti-tumor activity of EMB-15 will also be assessed.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-16
Trial Details
NCT Number NCT07607054
Lead Sponsor Shanghai EpimAb Biotherapeutics Co., Ltd.
Conditions Locally Advanced or Metastatic Solid Tumors
Enrollment 50 participants
Start Date 2026-05-26
Primary Completion 2029-05-31 (estimated)
Study Completion 2029-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-15